Exact Sciences and Pfizer Extend and Amend Cologuard® Promotion Agreement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St indexes fall to two-week lows as rising bond yields, disappointing Walmart results drag
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Exact Sciences (EXAS) New Deal with Pfizer a 'Win-Win' - Cowen
October 7, 2020 10:51 AM EDTCowen analyst Doug Schenkel reiterated an Outperform rating and $135.00 price target on Exact Sciences (NASDAQ: EXAS) calling the new Pfizer agreement a "win-win" for EXAS.
The analyst commented, "EXAS and PFE have amended the 2018 Cologuard co-promotion agreement which (1) extends a largely successful deal, (2)... More
